Symptoms and quality of life in patients with chronic obstructive pulmonary disease treated with aclidinium in a real-life setting

References

• Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of COPD. 2014. Available from: www.goldcopd.org [cited 26 January 2016].
   Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009; 34: 648–54.
   Google Scholar
• Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, etal. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011; 37: 264–72. doi: http://dx.doi.org/10.1183/09031936.00051110 [PubMed Abstract].
   Google Scholar
• Price D, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis. 2013; 8: 595–603. doi: http://dx.doi.org/10.2147/COPD.S48570 [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• O'Hagan P, Chavannes NH. The impact of morning symptoms on daily activities in chronic obstructive pulmonary disease. Curr Med Res Opin. 2014; 30: 301–14. doi: http://dx.doi.org/10.1185/03007995.2013.857648 [PubMed Abstract].
   Google Scholar
• Stallberg B, Janson C, Johansson G, Larsson K, Stratelis G, Telg G, etal. Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS). Prim Care Respir J. 2014; 23: 38–45.
   Google Scholar
• Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium in COPD patients (ACCORD COPD I). COPD. 2012; 9: 90e101. doi: http://dx.doi.org/10.3109/15412555.2012.661492.
   Google Scholar
• Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, etal. Efficacy and safety of aclidinium compared with placebo and tiotropium in patients with moderate-to severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD. 2013; 10: 511–22. doi: http://dx.doi.org/10.3109/15412555.2013.814626 [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, etal. Efficacy of aclidinium 400 mg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012; 141: 745–52. doi: http://dx.doi.org/10.1378/chest.11-0406 [PubMed Abstract].
   Google Scholar
• Jones PW, Tabberer M, Chen W. Creating scenarios of the impact of COPD and their relationship to COPD assessment test (CAT™) scores. BMC Pulm Med. 2011; 11: 42.
   Google Scholar
• Kon SSC, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, etal. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014; 2: 195–203.
   Google Scholar
• Likert R. A technique for the measurement of attitudes. Arch Psychol. 1932; 140: 1–55.
   Google Scholar
• Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, etal. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180: 741–50. doi: http://dx.doi.org/10.1164/rccm.200904-0492OC on August 13, 2009 [PubMed Abstract].
   Google Scholar
• Lee SD, Xie CM, Yunus F, Itoh Y, Ling X, Yu WC, etal. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: a randomized, multicentre study in East Asia. Respirology. 2015; 21: 119–27. doi: http://dx.doi.org/10.1111/resp.12646 [PubMed Abstract].
   Google Scholar
• Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcia Gil E, Caracta C, etal. Long-term safety and efficacy of twice-daily aclidinium in patients with COPD. Respir Med. 2013; 107: 1957–65. doi: http://dx.doi.org/10.1016/j.rmed.2013.07.001 [PubMed Abstract].
   Google Scholar
• Marth K, Schuller E, Pohl W. Improvements in patient-reported outcomes: a prospective, non-interventional study with aclidinium for treatment of COPD. Respir Med. 2015; 109: 616–24.
   Google Scholar
• Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009; 25: 2043–8.
   Google Scholar
• Roche N, Small M, Broomfield S, Higgins V, Pollard R. Real world COPD: association of morning symptoms with clinical and patient reported outcomes. COPD. 2013; 10: 679e86. doi: http://dx.doi.org/10.3109/15412555.2013.844784.
   Google Scholar
• Lange P, Marott JL, Vestbo J, Nordestgaard BG. Prevalence of night-time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014; 43: 1590–8.
   Google Scholar
• Cai Q, Sullivan SD, Stephenson JJ, Tan H, Kavati A, Mocarski M, etal. Health-related quality of life and work productivity of employed COPD patients with nighttime and early morning symptoms. Am J Respir Crit Care Med. 2013; 187: A2939.
   Web of Science ®Google Scholar
• Stephenson JJ, Cai Q, Mocarski M, Tan H, Doshi JA, Sullivan SD. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chorn Obstruct Pulmon Dis. 2015; 10: 577–86.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Worth H, Soler Cataluña JJ, Price D, De Benedetto F, Roche N, etal. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014; 15: 122.
   Google Scholar
• Omachi TA, Blanc PD, Claman DM, Chen H, Yelin EH, Julian L, etal. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012; 13: 476e83. doi: http://dx.doi.org/10.1016/j.sleep.2011.12.007.
   Google Scholar
• Agusti A, Hedner J, Marin JM, Barbe F, Cazzola M, Rennard S. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011; 20: 183–94. doi: http://dx.doi.org/10.1183/09059180.00004311 [PubMed Abstract].
   Google Scholar
• Price D, Lee AJ, Sims EJ, Kemp L, Hillyer EV, Chisholm A, etal. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim Care Respir J. 2013; 22: 161–8.
   Google Scholar